Shandong University - Shandong Cancer Hospital | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)	Advanced Non-small Cell Lung Cancer, HER2 Mutation	Recruiting	Phase 3	2026-09-23		NCT06452277
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum	Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Nutritional and Metabolic Diseases, colonic disorder, colorectal adenocarcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, metabolic disease, neoplasm	Recruiting	Phase 2	2026-09-16		NCT07811193
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement	Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm	Recruiting	Phase 2	2026-09-01		NCT05727176
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)	Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation	Recruiting	Phase 1 / Phase 2	2026-08-12		NCT05099172